Relative Dispersions of Intra-albumin Transit Times across Rat and Elasmobranch Perfused Livers, and Implications for Intra- and Inter-species Scaling of Hepatic Clearance using Microsomal Data
- 1 August 1998
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 50 (8) , 865-870
- https://doi.org/10.1111/j.2042-7158.1998.tb04001.x
Abstract
It is recognized that vascular dispersion in the liver is a determinant of high first‐pass extraction of solutes by that organ. Such dispersion is also required for translation of in‐vitro microsomal activity into in‐vivo predictions of hepatic extraction for any solute. We therefore investigated the relative dispersion of albumin transit times (CV2) in the livers of adult and weanling rats and in elasmobranch livers. The mean and normalized variance of the hepatic transit time distribution of albumin was estimated using parametric non‐linear regression (with a correction for catheter influence) after an impulse (bolus) input of labelled albumin into a single‐pass liver perfusion. The mean±s.e. of CV2 for albumin determined in each of the liver groups were 0·85 ± 0·20 (n = 12), 1·48 ± 0·33 (n = 7) and 0·90 ± 0·18 (n = 4) for the livers of adult and weanling rats and elasmobranch livers, respectively. These CV2 are comparable with that reported previously for the dog and suggest that the CV2 of the liver is of a similar order of magnitude irrespective of the age and morphological development of the species. It might, therefore, be justified, in the absence of other information, to predict the hepatic clearances and availabilities of highly extracted solutes by scaling within and between species livers using hepatic elimination models such as the dispersion model with a CV2 of approximately unity.Keywords
This publication has 18 references indexed in Scilit:
- An Optimized Model for Rat Liver Perfusion StudiesJournal of Surgical Research, 1996
- Prediction of the maximal tolerated dose (MTD) and therapeutic effect of anticancer drugs in humans: integration of pharmacokinetics with pharmacodynamics and toxicodynamicsCancer Treatment Reviews, 1995
- Accuracy of Numerical Inversion of Laplace Transforms for Pharmacokinetic Parameter EstimationJournal of Pharmaceutical Sciences, 1995
- Axial tissue diffusion can account for the disparity between current models of hepatic elimination for lipophilic drugsJournal of Pharmacokinetics and Biopharmaceutics, 1992
- Residence time distributions of solutes in the perfused rat liver using a dispersion model of hepatic elimination: 1. Effect of changes in perfusate flow and albumin concentration on sucrose and taurocholateJournal of Pharmacokinetics and Biopharmaceutics, 1990
- Availability predictions by hepatic elimination models for Michaelis-Menten kineticsJournal of Pharmacokinetics and Biopharmaceutics, 1989
- Effects of perfusate flow rate on measured blood volume, disse space, intracellular water space, and drug extraction in the perfused rat liver preparation: Characterization by the multiple indicator dilution techniqueJournal of Pharmacokinetics and Biopharmaceutics, 1988
- Models of hepatic elimination: Comparison of stochastic models to describe residence time distributions and to predict the influence of drug distribution, enzyme heterogeneity, and systemic recycling on hepatic eliminationJournal of Pharmacokinetics and Biopharmaceutics, 1988
- Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion modelJournal of Pharmacy and Pharmacology, 1986
- Hepatic Eliminatilon—Dispersion ModelJournal of Pharmaceutical Sciences, 1985